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tration with CD43- and ED1-positive cells in glomeruli andMycophenolate mofetil prevents the progressive renal failure
interstitium was two to five times lower in MMF-treated ratsinduced by 5/6 renal ablation in rats.
(P , 0.01). Expression of adhesion molecules CD18 and CD11bBackground. Extensive renal ablation is associated with pro-
was similarly reduced.gressive sclerosis of the remnant kidney. Because lymphocytes
Conclusion. MMF ameliorates the progressive renal damageand monocytes accumulate in the remnant kidney, it is likely
that they play a role in the renal scarring. Therefore, we treated in the remnant kidney after 5/6Nx. This effect is associated with
rats with 5/6 nephrectomy (5/6Nx) with mycophenolate mofetil a reduction in the infiltration of lymphocytes and monocytes,
(MMF), a drug that has an antiproliferative effect and that whereas glomerular hypertrophy and systemic hypertension
suppresses the expression of intercellular adhesion molecules. are unchanged.
Methods. Sprague-Dawley rats with 5/6Nx received MMF
(30 mg · kg21 · day21 by daily gastric gavage, N 5 15) or vehicle
(N 5 16). Ten additional rats were sham operated. All rats
The progression of renal damage resulting from re-were fed a 30% protein diet. Body weight, serum creatinine,
and urinary protein excretion were determined weekly. Lipid duced nephron mass has been extensively studied in the
peroxidation, as a measure of oxidative stress observed by 5/6Nx model in the rat, as described originally by Shima-
urinary malondialdehyde determinations, was performed every mura and Morrison [1]. Classic studies by Hostetter et
two weeks. Histologic studies were done in the remnant kidney
al demonstrated that this experimental model was char-four weeks (9 rats from the vehicle-treated group, 7 rats from
acterized by progressive glomerulosclerosis and chronicthe MMF group, and 5 sham-operated rats) and eight weeks
after surgery (the remaining rats). Glomerular volume, sclero- renal failure [2]. The remnant nephron units developed
sis in glomeruli (segmental and global) and interstitium (semi- glomerular hypertension, increased single nephron glo-
quantitative scale), infiltrating lymphocytes and macrophages merular filtration rate, and glomerular hypertrophy, and(CD43- and ED1-positive cells), and expression of adhesion
over the previous 15 years, all of these factors have beenmolecules (CD54, CD18, and CD11b) were analyzed.
postulated to play a pathogenetic role in the progressiveResults. MMF treatment prevented the progressive incre-
ment in serum creatinine and the proteinuria observed in the scarring of the kidney [3]. Surviving nephrons have in-
5/6 nephrectomized rats during the eight weeks of observation creased oxygen consumption and are subjected to oxi-
(P , 0.01). Weight gain was comparable in the MMF-treated
dant stress [4].and sham-operated rats, whereas weight gain was decreased
Because the initial event in the subtotal renal ablationin untreated 5/6 nephrectomized rats. Excretion of malondial-
dehyde increased after surgery but returned sooner to control model is an increase in glomerular pressure, treatment
levels in the MMF-treated rats. Increments in glomerular size strategies have usually been directed to correct this he-
and mean arterial blood pressure induced by renal ablation modynamic disturbance, specifically, to reduce intra-were not modified by MMF treatment. Eight weeks after sur-
glomerular pressure. Correction of this pathophysiologicgery, segmental sclerosis was present in 48.4 6 8.35% (6 sd)
event and normalization of permselectivity properties ofglomeruli in the vehicle-treated group versus 25 6 10.5% in
the MMF-treated group (P , 0.001). Interstitial fibrosis was the glomerular capillary barrier [5] are major mecha-
reduced significantly with MMF treatment (P , 0.001). Infil- nisms underlying the protective effect on renal function
observed with angiotensin-converting enzyme inhibition
and low-protein diet in several models of renal diseaseKey words: sclerosis, remnant kidney, scarring, adhesion molecules,
proteinuria, interstitial fibrosis. in the experimental animal and in humans [6].
Less commonly, treatments have been directed to
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treatment, which prevents microthrombosis [7], as well rat chow containing 30% protein (Purina, St. Louis, MO,
as Ticlopidine, a drug with a wide spectrum of inhibitory USA) and tap water.
actions on platelets and platelet–cell interactions, retards After obtaining blood samples for serum creatinine
the progression of renal failure in the remnant kidney and 24-hour urine for determination of proteinuria and
model [8]. More recently, Shimizu et al have reported urinary malondialdehyde excretion, 40 rats had 5/6Nx
that administration of Pirfenidone, a compound that pre- (mentioned later here), and 10 rats had a sham operation.
vents and reverses extracellular matrix accumulation, Nine rats in the group that had 5/6Nx died during surgery
ameliorates the histologic damage in the remnant kidney or in the following 48 hours. Five days after surgery,
of the rat with 5/6Nx [9]. the surviving rats in the 5/6Nx group were randomly
Largely undefined is the role played by infiltrating subdivided in two groups, one of which received MMF
lymphocytes and macrophages in the development of (5/6NxMMF group, N 5 15) the other one received vehi-
glomerulosclerosis triggered by a reduction of nephron cle (5/6Nx, N 5 16). Four of these rats died in the subse-
mass. There is limited information on lymphocyte accu- quent four weeks (two from the 5/6NxMMF group and
mulation in this model. However, monocyte/macrophage two from the 5/6Nx group). Histologic studies were done
infiltration occurs early [10, 11], and their numbers in- four and eight weeks after surgery. At the four-week
crease fourfold to fivefold in the glomeruli and tubuloin- endpoint, nine rats from the 5/6Nx group, seven rats
terstitial areas of the remnant kidney [12, 13]. Therefore, from the 5/6NxMMF group, and five sham-operated rats
it is likely that these cells play a significant role in the were sacrificed. The remaining rats (5 rats from the sham-
subsequent development of fibrosis. In fact, cytokines operated group, 5 rats from the 5/6Nx group, and 6 rats
produced by infiltrating cells appear to mediate renal from the 5/6NxMMF group) were sacrificed eight weeks
scarring in this experimental model [10]. after surgery.
Mycophenolate mofetil (MMF) is a new immunosup- Body weight, serum creatinine, and urinary protein
pressant agent in which the active component, mycophe- excretion were determined weekly. Urinary malondialde-
nolic acid, is an inhibitor of inosine 59-monophosphate hyde (MDA) determinations were done every two weeks.
dehydrogenase, which controls the synthesis of guano- Histologic and immunohistologic studies were done in
sine triphosphate [14, 15]. MMF depletes guanosine tri- remnant kidneys and in sham-operated animals at the
phosphate pools in lymphocytes and monocytes and sup- time of sacrifice.
presses the de novo synthesis of purines, thereby exerting
a selective and reversible antiproliferative activity on Dose of mycophenolate mofetil
these cells. In addition, the expression of intercellular
Preliminary studies were done to determine the
adhesion molecules, which is critical for the migration
maximal tolerated dose of MMF. Doses higher than 30of leukocytes from circulation and their subsequent accu-
mg · kg21 · day21 were usually associated with diarrhea;mulation in the tissues, is suppressed by this drug [16].
consequently, this dose was chosen. Daily gastric gavageTherefore, we decided to investigate whether treat-
was used to administer 30 mg · kg21 · day21 of MMFment with MMF would reduce the renal cellular infiltra-
diluted in 200 ml of water to the rats of the 5/6NxMMFtion and the expression of adhesion molecules, as well
group. Because mycophenolate (CellCept; Roche Phar-as the oxidant-induced lipid peroxidation observed after
maceutical Co., Caracas, Venezuela) is insoluble in wa-5/6Nx, and whether these modifications would be associ-
ter, we prepared each dose individually and agitated theated with improvement in the progression of renal dis-
mixture vigorously to obtain a suspension, and then theease. We found that deterioration of renal function and
suspension was immediately given to the rat before theproteinuria, which is characteristic of this model, was
MMF precipitated. Rats in the 5/6Nx group and shamprevented and that the hallmark histologic changes were
groups received the same volume of water by the samemarkedly improved. Because the hematologic, liver, and
route of administration daily.renal toxicity of MMF are relatively minor [17, 18] and
this drug is used with relative safety in the long-term
Surgical procedurestreatment of renal transplantation, MMF could be poten-
Subtotal renal ablation was done in a single surgicaltially useful to retard the progressive damage associated
procedure by subcapsular removal of the right kidneywith reduced nephron mass in humans.
and selective infarction of two thirds of the left kidney
by ligation of the posterior and one or two of the anterior
METHODS extrarenal branches of the renal artery, to leave approxi-
Design of the study and experimental groups mately one sixth of the total kidney tissue mass. Sham
operations consisted in laparotomy and manipulation ofStudies were done in 50 male Sprague-Dawley rats
the kidneys and renal pedicle without destruction of re-weighing 200 to 280 g at the start of the experiments.
Throughout the study, all rats were fed ad libitum with nal tissue.
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Determination of lipid peroxidation sclerosis in superficial and juxtamedullary sections. Glo-
merulosclerosis was evaluated in PAS-stained tissue andWe used the method of Ohkawa et al to determine
was defined as the increment of PAS-positive material,thiobarbituric acid reactive substances, an index of lipid
with loss of cellular elements, collapse of capillary lumina,peroxidation [19]. MDA was measured in 24-hour urine
and entrapment of amorphous hyaline material associ-centrifuged at 2000 r.p.m. and processed the same day.
ated or not with adhesions to Bowman’s capsule. Sclero-Four hundred microliters of the sample were added to
sis involving more than 80% of the glomerular tuft wasa reaction mixture consisting of 200 ml of 8.1% sodium
considered global, and sclerosis involving less than 80%dodecyl sulfate, 1.5 ml of 20% acetic acid (pH 3.5), 1.5
was considered segmental. No attempt was made to sub-ml of 0.5% thiobarbituric acid, and 400 ml of bidistilled
classify the segmental lesions in accordance with thewater. This mixture was heated at 958C in water bath
percentage involvement of the glomerulus. At least 100for 60 minutes. After removal from the water bath, 1 ml
glomeruli were evaluated per biopsy. Results are ex-of water and 5 ml N-butanol-pyridine were added, and
pressed as the percentage glomeruli examined (more thanthe mixture was agitated and centrifuged at 2000 g for
100 per biopsy) showing segmental or global sclerosis.15 minutes. The upper organic layer was pipetted, and
Tubulointerstitial lesions. Severity of tubular dilationthe absorbance of this fraction was read at 532 nm in a
and atrophy, as well as tubulointerstitial infiltration (he-Shimatzu model UV21100 S spectrophotometer (Kyoto,
matoxylin and eosin staining) and fibrosis (trichromeJapan). Malondialdehyde bis-dimethyl acetal was used
staining), were evaluated individually, determining theas external standard. Results were expressed as nmol of
percentage in the biopsy section affected by the corre-MDA excreted in 24 hours.
sponding finding with the help of a grid-fitted eyepiece.
Laboratory determinations Gradation of damage (0 to 51) was done by modifying
the scale used by Zoja et al as follows: 0 5 changes inProteinuria was determined in 24-hour urine collec-
less than 10% of the histologic section; 11 5 changestions by the sulfosalicylic acid method and the serum
in up 20% of the section; 21 5 changes in up to 40%creatinine by modification of the Jaffe´ reaction in auto-
of the section; 31 5 changes in up to 60% of the section;analyzer methodology.
41 5 changes in up to 80% of the section; 51 5 changes
Tissue preparation in more than 80% of the section [8]. The average score
obtained in the sections of each biopsy (10 to 15 sectionsFrom every animal, coronal sections of remnant renal
per biopsy) was used as the score of the biopsy.tissue were obtained at the time of sacrifice. One frag-
ment was fixed in 15% formalin, and 10 were embedded
Immunofluorescence studiesin Paraplast Plus (Monoject, Sherwood Medical Scien-
Identification of intercellular adhesion molecules wastific Division, St. Louis, MO, USA); the rest were in-
done in frozen 3 mm sections by indirect immunofluo-cluded in Tris buffered saline (TBS) freezing medium
rescence technique, as described in previous publications(Triangle Biomedical Sciences, Durham, NC, USA) and
[20, 21] using the monoclonal antibodies listed later. Aswere immediately frozen in dry ice and acetone and were
secondary antibody we used fluorescein-conjugated af-stored at 2708C.
finity-pure F(ab9)2 rat antimouse IgG with minimal cross
Light microscopy studies reactivity with rat proteins (Accurate Chemical & Scien-
tific Corp., Westbury, CT, USA) at a concentration ofParaffin-embedded sections were stained with hema-
60 mg/ml (1:50). Ethidium bromide was used for nucleartoxylin eosin, Masson’s Gomori’s stain, and periodic
staining.acid-Schiff reagent (PAS). Coronal sections cut at 4 mm
The following monoclonal antibodies were used: anti-thickness, including superficial and juxtamedullary glo-
CD43 (Accurate Chemical & Scientific Corp., Westbury,meruli, were evaluated.
NY, USA; mouse IgG1 clone W3/13, distribution in TEvaluation of histologic damage. Sections were exam-
lymphocytes, concentration 5 5 mg/ml); anti-ED1 (Accu-ined by two investigators without previous knowledge
rate Chemical & Scientific; mouse IgG1, distribution inof the experimental group of the animal from which the
monocytes, concentration 5 30 mg/ml); anti-ICAM1tissue was taken. At least 10 sections were analyzed
(CD54; Seikegaku Corp. Tokyo, Japan; IgG1, distribu-for each kidney, and the evaluation that was assigned
tion in endothelial cells, monocytes, T and B lymphocytes,represented the mean values of these sections. Agree-
epithelial cells, dendritic cells, mesangial cells; concentra-ment between the two observers was within 10%. Evalu-
tion 5 10 mg/ml); anti-CD11b (Biosource International,ation was done as follows.
Camarillo, CA, USA; mouse IgG2 A, distribution inGlomerular sclerosis. Glomerular lesions were evalu-
monocytes/macrophages, neutrophils; concentration 5 5ated by determining the number of normal glomeruli and
the number with either segmental or total glomerular mg/ml) and anti-LFA1 (CD18; Seikegaku Corp.; IgG1,
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distribution in lymphocytes, monocytes, neutrophils; con-
centration 5 10 mg/ml).
Double-staining procedures were done as follows: The
monoclonal antibody (mAb) used to identify the inte-
grins (mAb anti-CD18 or anti-CD11b) was applied to
the tissue (concentrations listed earlier here) and was
incubated in a humid chamber at room temperature for
45 minutes. Afterward, tetramethylrhodamine isothiocy-
anate (TRIC)-conjugated, affinity-pure F(ab9)2 rat anti-
mouse IgG, with minimal cross-reaction with rat proteins
(Accurate Chemical & Scientific) was added. After wash-
ing for 10 minutes with PBS 0.01 m, 0.15 m NaCl (one
change of PBS) and 100 ml of blocking solution (PBS
0.01 m, 0.15 m NaCl containing 10% fetal calf serum and
Fig. 1. Serum creatinine concentration in sham-operated animals (h)10% goat serum) were added, incubated for 10 minutes,
and rats with reduction in renal mass, untreated (5/6Nx, j) and treatedand washed as described earlier here. Afterward, the with mycophenolate mofetil (5/6NxMMF, d). Data from five to eight
tissues were incubated with the mAb used to identify weeks correspond to five animals in each group; otherwise, the values
represent 10 to 16 animals in each group (Methods section, experimentalthe leukocyte populations (mAb anti-CD43 or mAb anti-
design). Abbreviations are: B, baseline; weeks, weeks after surgery.ED1 at the dilutions described earlier) and were then
*P , 0.05, **P , 0.01, ***P , 0.001 vs. sham. Bars are standard
reacted with 50 ml of fluorescein-conjugated, affinity- deviation. The differences between the 5/6Nx group and the MMF
pure F(ab9)2 rat antimouse IgG (20 mg/ml) with minimal treated group are also significant (P , 0.001) after the fourth week.
cross-reaction with rat proteins (Accurate Chemical &
Scientific). As a control for the double-staining procedure,
five tissues were double stained with CD18 and ED1, as test or Kruskal Wallis tests with Dunn’s multiple compar-
described earlier here. ison post-test were used. Differences were considered
Tissues were examined with a Zeiss microscope with significant when P was less than 0.05.
epifluorescence system, phase contrast, and appropriate
filters. Cells with red nuclei surrounded by a green cyto-
RESULTSplasmatic membrane were counted as positive. Counting
was done with the help of a grid-fitted eyepiece. Within Figure 1 shows the serial changes in serum creatinine
the glomerular tuft, staining results were expressed as concentration observed in the sham-operated and in the
positive cells per glomerular cross-section, with the ex- rats with 5/6 reduction in renal mass with (5/6NxMMF)
ception of CD54 staining that was expressed as a 11 to and without (5/6Nx) treatment with MMF. The un-
41 score, described previously [17], which takes into treated 5/6Nx group of rats experienced a progressive
account the number of positive cells and the intensity of rise in serum creatinine (P , 0.01 vs. baseline) from the
the fluorescent staining. In the interstitial areas, results second week up to the seventh to eighth week after
were expressed as positive cells per mm2. nephrectomy when it appeared to reach a plateau, at
levels of 156 6 6.61 mmol/liter, approximately 2.4 timesGlomerular volume
above control levels. The levels of serum creatinine the
At least 100 glomeruli in each kidney tissue were ex-
5/6NxMMF group and in the sham-operated group wereamined, and the glomerular diameter was measured us-
lower than in the untreated 5/6Nx rats (P , 0.001 in Fig.ing a microscopic scale attached to the ocular lens. Then,
1). In contrast, the 5/6NxMMF group had essentiallythe mean random cross-sectional glomerular area (AG) similar serum creatinine levels than the sham-operatedwas calculated, and the glomerular volume (VG) was group the first four weeks after surgery. Thereafter, thedetermined using the following formula:
level of the creatinine in 5/6NxMMF group was slightly
VG 5 (b/k 3 AG)3/2 above the levels in the sham-operated group but was
steady at each time interval (Fig. 1).where b 5 1.38 is the shape coefficient for spheres, the
Urinary protein excretion is shown in Figure 2. Theidealized shape of the glomerular tuft, and k 5 1.1 is
animals receiving MMF (5/6NxMMF) and the sham-the size distribution coefficient [22].
operated group showed essentially similar levels of pro-
Statistical analysis teinuria throughout the eight-week observation period.
Urinary protein excretion in these groups (5/6NxMMFResults are expressed as mean 6 sd. Comparisons
group and sham-operated group) is unchanged from thebetween groups were done by one-way analysis of vari-
baseline levels. In contrast, the untreated animals withance followed by Tukey-Kramer post-tests. When differ-
reduced renal mass (5/6Nx group) showed a progressiveences in the standard deviation of the groups under anal-
ysis were significant, nonparametric Mann–Whitney rank increment in proteinuria.
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Fig. 2. Urinary protein excretion in sham-operated animals (h) and Fig. 3. Urinary malondialdehyde (MDA) excretion in sham-operated
rats with reduction of renal mass untreated (5/6Nx, j) and treated with animals (h) and rats with reduction of renal mass untreated (5/6Nx, j)
mycophenolate mofetil (5/6NxMMF, d). Data from five to eight weeks and treated with mycophenolate mofetil (5/6NxMMF, d). From five to
correspond to five animals in each group; otherwise, the values represent eight weeks, all groups consisted of five animals each; otherwise, all
10 to 16 animals in each group (Methods section, experimental design). values represent at least 10 animals in each group (Methods section,
Bars are standard deviation. Abbreviations are: B, baseline; weeks, weeks experimental design). Bars are standard deviation. Abbreviations are:
after surgery. *P , 0.01 and **P , 0.001 vs. sham and MMF group. B, baseline; weeks, weeks after surgery. *P , 0.001 vs. sham; **P , 0.01
vs. sham. The difference between the 5/6Nx group and the 5/6NxMMF
group at three to four weeks and at five to six weeks is also significant
(P , 0.001).
All animal groups had similar weights (g) at the begin-
ning of the experiment (5/6Nx group 5 255 6 11.42,
5/6NxMMF group 5 236.9 6 10.09, sham-operated of the glomeruli in sham-operated animals and increased
group 5 255 6 5.00) and gained weight during the period 13 times at four weeks and 17 times at eight weeks after
of observation. However, the 5/6NxMMF group and the 5/6Nx in the untreated group (5/6Nx group). Eight weeks
sham-operated groups gained weight similarly at four after renal ablation, segmental glomerulosclerosis in rats
weeks (5/6NxMMF group 5 320 6 6.70, sham-operated treated with MMF (5/6NxMMF group) was 25 6 10.5%,
group 5 315 6 4.30) and at eight weeks (5/6Nx,MMF half of the value in untreated rats at the same period of
group 5 409 6 2.45, sham-operated group 5 411.3 6 time (P , 0.001).
2.40); in contrast, the 5/6Nx group gained less weight at Tubular dilation and atrophy, as well as tubulointersti-
four weeks and eight weeks (286.1 6 9.44 and 338 6 tial infiltration and fibrosis, were substantially reduced
8.00, respectively, P , 0.01). in the 5/6NxMMF group. In contrast, the untreated ne-
Mean arterial blood pressure at the time of sacrifice phrectomized animals (5/6Nx group) had increasing se-
(4 weeks after surgery) was 121.1 6 10.33 in the sham- verity of tubular and interstitial damage, involving 40%
operated rats, 165.5 6 16.5 in the 5/6Nx group (P , to 80% of the examined remnant renal tissue after eight
0.001 vs. sham), and 158.3 6 15.4 in the 5/6NxMMF weeks (Table 1).
group (P , 0.01 vs. sham). Figure 4A shows typical sclerotic changes in glomeruli
Figure 3 shows the urinary excretion of MDA. Both and interstitium in untreated animals, in contrast with
groups of nephrectomized rats (5/6Nx group and animals treated with MMF (Fig. 4B).
5/6NxMMF group) had their urinary excretion of MDA Cells expressing adhesion molecules (CD54, CD18,
doubled after surgery; however, the group treated with and CD11b) and CD43- and ED1-positive cells in the
MMF showed a progressive decrease in urinary MDA glomeruli and in tubulointerstitial areas are shown in
starting three to four weeks after surgery, reaching con- Tables 2 and 3, respectively, as well as in Figure 4 C–F,
trol levels during the fifth to sixth week. In contrast, the and Figure 5.
untreated animals (5/6Nx group) increased the MDA In biopsies examined four and eight weeks after sur-
excretion nine times, peaking at the fourth week and gery, the number of lymphocytes (CD43-positive cells)
decreasing thereafter (Fig. 3). and macrophages (ED1-positive cells) in the glomeruli
The histologic observations are shown in Table 1. The (Table 2) and interstitium (Table 3) was not statistically
glomerular volume is higher in the two groups of rats different in sham-operated rats and in rats treated with
with reduced renal mass. There were no significant differ- MMF (5/6NxMMF group). In contrast, the untreated
ences in the glomerular hypertrophy in the 5/6Nx group 5/6Nx group showed values three to four times higher
and the 5/6NxMMF group. Glomerular sclerosis, both (Table 2).
Four weeks after surgery, the untreated 5/6Nx groupsegmental and global, was present in a small percentage
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Table 1. Histological observations
4 weeks after surgery 8 weeks after surgery
Sham 5/6 Nx 5/6 Nx 1 MMF Sham 5/6 Nx 5/6 Nx 1 MFF
(N 5 5) (N 5 9) (N 5 7) (N 5 5) (N 5 5) (N 5 5)
VG lm3 3 10 6 1.6160.10 2.2360.43 2.27 60.34 1.8160.42 2.6160.21 2.5860.90
Glomerular sclerosis
Segmental % 3.060.71 38.764.33 21.7 69.41a 2.860.83 48.468.35 25.0610.51a
Global % 0.060.00 7.5763.65 4.29 66.45 0.060.00 20.6615.27 6.20 67.95b
Tubular dilation & atrophy (0–5) 0.060.00 2.8960.78 0.71 60.76a 0.060.00 4.260.45 0.860.84a
Interstitial infiltration (0–5) 0.060.00 1.5660.73 1.0 60.89 0.060.00 3.861.48 1.262.16
Interstitial fibrosis (0–5) 0.060.00 1.6760.50 0.42 60.54a 0.060.00 2.060.71 0.4 60.89b
Segmental and global glomerular sclerosis expressed as the percent of the glomeruli examined presenting the corresponding lesion. Tubulointerstitial damage was
graded according to the percent of the biopsy affected by the corresponding finding (see Methods section). N corresponds to the number of renal biopsies in each
group; the value in each biopsy is the mean of 10-15 sections.
Statistical significances between 5/6NxMMF vs. 5/6Nx are: a P , 0.001, b P , 0.05. The percentage glomeruli showing global sclerosis in the 5/6Nx group is higher
at 8 weeks than at 4 weeks (P , 0.001). Data in untreated 5/6Nx are different (P ranging from ,0.05 to ,0.001) from data in sham operated rats.
had increased expression of adhesion molecules CD45, 5/6Nx and the 5/6NxMMF groups were similarly elevated
CD18, and CD11b (Tables 2 and 3). Eight weeks after with respect to the sham-operated group. The doses of
surgery, the expression of CD54 in the untreated 5/6Nx MMF used in this work are not expected to have a sig-
group had decreased, whereas in contrast, CD11b had nificant antiplatelet effect or to decrease the numbers of
more than doubled in tubulointerstitial areas (Table 3). circulating leukocytes, but this possibility was not ruled
Sham-operated animals and 5/6Nx rats treated with out in this study.
MMF had essentially similar expression of CD54, CD18, Other recent studies addressing the final common
and CD11b at four weeks (Table 2). At eight weeks, the pathway by which hemodynamic alterations induce renal
only significant difference between the sham-operated scarring are those of Shimizu et al, who used Pirfenidone,
and 5/6Nx group was a reduction in the interstitial infil- a drug that prevents and reverses collagen accumulation
tration of cells expressing CD54 in the MMF-treated [9]. They found attenuation of the chronic renal failure
group (Table 3). in the rats with 5/6Nx [9].
Suppression of lymphocyte activity and monocyte/
macrophage infiltration is yet another strategy of poten-DISCUSSION
tial use for amelioration of the progressive renal damage
The 5/6Nx model in the rat has been widely used to
resulting from renal ablation. Macrophages are knownevaluate the effect of treatment strategies on the progres-
to participate in the inflammatory reaction, producing asive scarring of the kidney that is associated with exten-
number of soluble mediators, including cytokines, prote-sive renal ablation. Because the initial effects of the
ases, and free oxygen radicals [27], and several studiesreduction of nephron mass involves hypertension and
have shown that macrophage infiltration and prolifera-hyperfiltration of the remnant nephron units, a vast ma-
tion are prominent findings in the remnant kidney [11–jority of research efforts have been directed to determine
13, 28]. Furthermore, Schiller et al have recently demon-if the correction of the altered hemodynamics improves
strated that mechanical injury resulting from glomerularthe renal damage. Understandably, drugs that lower sys-
capillary hypertension induces up-regulation of mono-temic and glomerular pressure are among the most
cyte chemoattractant protein-1 (MCP-1) [10]. Interest-prominently studied [23–26].
ingly, a low-protein diet modulates the expression ofOther treatment strategies have been investigated less
MCP-1 [10], which suggests that protein restriction, infrequently. Pukerson et al showed that thrombotic mech-
addition to improving glomerular hemodynamics in theanisms are important in the progression of the glomeru-
remnant nephrons, could have beneficial effects resultinglar lesion and that heparin had a beneficial effect [7].
from inhibition of macrophage infiltration.Suppression of platelet adhesion and platelet-derived
Mycophenolate mofetil is the morpholinoethytl esterfactors was a treatment modality chosen by Zoja et al,
of mycophenolic acid, and it inhibits inosine 59-mono-who found that Ticlopidine, a drug with a wide spectrum
phosphate dehydrogenase, which controls the de novoof antiplatelet effects, improved the progressive renal
synthesis of guanosine triphosphate [29]. This drug hasdamage of the remnant kidney [8]. Interestingly, the
a relatively specific effect on lymphocytes because otherbeneficial effects of this treatment occur without modifi-
cells have alternative purine synthesis pathways notcation of the systemic blood pressure [8], which also
blocked by MMF. In the experimental setting of experi-appears to be the case in the improvement induced with
MMF reported here, as the blood pressure levels in the mental renal ablation, MMF is a drug well suited for the
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Fig. 4. Changes observed by light microscopy and lymphocyte and macrophage infiltration of remnant kidneys four weeks after 5/6Nx. Severe
segmental sclerosis (approximately 60% of the glomerular tuft) observed in untreated rat (receiving vehicle; A) is contrasted with essentially
normal glomerular appearance in rat treated with MMF (B). In addition, interstitial fibrosis is evident in untreated rat and absent in the biopsy
from the rat treated with MMF (Mason’s Trichromic stain, original magnification &time;400). Immonuhistology showing remnant kidney tissue
stained with mAb anti-CD43 (C, untreated rat; D, rat treated with MMF) and with mAb anti-ED1 (E, untreated rat; F, rat treated with MMF).
Original magnification was 3630.
purpose of testing the effects of suppressing macrophage brane glycoproteins, which are ligands of the selectin
adhesion molecules in the vascular endothelium [29]; ininfiltration and proliferation for several reasons. First,
MMF depletes the pools of guanosine triphosphate not addition, MMF inhibits up-regulation of CD18 in lym-
phocytes [30]. Consequently, the infiltration of mono-only in lymphocytes but also in monocytes and thereby
decreases the synthesis of fucose and mannose of mem- cytes, as well as lymphocytes, is inhibited by this drug
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Table 2. Cellular infiltration in the glomeruli
4 weeks 8 weeks
Positive cells Sham 5/6Nx 5/6NxMFF Sham 5/6Nx 5/6NxMFF
per gcs (N 5 5) (N 5 9) (N 5 7) (N 5 5) (N 5 5) (N 5 5)
CD43 1.1460.27 3.7261.30 1.4660.94b 0.4660.31 3.4760.54 1.1560.56a
ED1 0.7460.11 3.1460.48 0.9760.27b 0.8660.27 2.2860.37 1.2660.44b
CD54 1.2760.13 2.2160.79 0.8660.18a 0.8560.12 0.5460.11 1.0860.08a
CD18 0.9860.27 4.4461.45 1.9461.02a 1.2160.14 1.3060.25 0.8060.24b
CD11b 1.0460.60 4.7562.18 1.3060.22a 1.0760.70 3.5060.94 0.8360.16a
N corresponds to the number of biopsies studied; the value in each biopsy represents the mean of 10-15 sections.
Statistical significances between 5/6Nx MMF and 5/6 Nx are: a P , 0.001, b P , 0.01. In the 5/6Nx group, the differences between the 4th and 8th week in CD54
and CD18 are significant (P , 0.01). The data of untreated 5/6Nx are significantly different (P ranging from ,0.05 to ,0.001) from the data in sham operated rats.
Table 3. Cellular infiltration in the interstitium
4 weeks 8 weeks
Positive cells Sham 5/6Nx 5/6NxMFF Sham 5/6Nx 5/6NxMFF
per mm2 (N 5 5) (N 5 9) (N 5 7) (N 5 5) (N 5 5) (N 5 5)
CD43 68.4656.5 135.6664.2 59.2639.3c 36.8617.3 431.2659.2 91.7659.9a
ED1 35.267.6 194.4661.2 34.069.6a 56.0611.6 140.0622.8 75.664.91a
CD54 252.0627.5 531.66216 314.46124c 261.6644.5 128.8615.3 73.6642.6c
CD18 25.4610.8 229.66132 72.6631.2b 41.6612.5 74.4619.9 75.0627.9
CD11b 32.0628.4 121.2643.1 25.2611.9 21.6617.8 352.86105 36.1621.8a
N corresponds to the number of biopsies studied; the value in each biopsy represents the mean of 10-15 sections.
Statistical differences between 5/6Nx MMF and 5/6Nx are: a P , 0.001, b P , 0.01, c P , 0.05. In the 5/6Nx group, the differences between the 4th and 8th week
in CD54 and CD18 are significant (P , 0.01). The data in the untreated 5/6Nx group are significantly different (p ranging from ,0.05 to ,0.001) from the data in
the sham operating group, except for CD18 positive cells at 8 weeks.
[30–32]. Second, MMF exerts a long-term inhibition of after four weeks in the 5/6NxMMF group, whereas
in contrast, it increases in the untreated 5/6Nx groupthe production of lymphocyte and macrophage-derived
cytokines [33], a valuable characteristic in the prevention (Table 1). Tubulointerstitial changes are ameliorated im-
portantly in the MMF-treated group (P . 0.05 vs. sham;of chronic scarring in the remnant kidney [34]. Third,
MMF, in contrast to other antirejection drugs, is not Table 1), in contrast with the changes seen in the 5/6Nx
group (Fig. 5 A, B).associated with renal toxicity [15] and is reasonably well
tolerated as a long-term treatment [17, 18]. The observed beneficial effect on renal scarring is
likely the result of direct and indirect actions of MMFTreatment with MMF completely prevented the pro-
teinuria induced by renal ablation. This protective effect because cytokine “cross-talk” between macrophages and
intrinsic renal cells is central to the cell proliferation andis maintained for at least eight weeks (Fig. 2). To our
knowledge, there is no direct effect of MMF on glomeru- matrix expansion that leads to glomerulosclerosis and
interstitial fibrosis [36]. Careful studies by Floege et allar permselectivity. Reduction of proteinuria, noted in
anecdotal reports of several kidney diseases treated with and Kliem et al have shown that in the remnant kidney
model, proliferation of intrinsic glomerular and tubuloin-this drug [35], is presumed to be a consequence of its
immunosuppressant properties, reduction of cellular in- terstitial cells is an early event in the development of
renal scarring; macrophage infiltration appears later andfiltration, and decrease in cytokine production. Renal
function is also markedly improved by MMF treatment. contributes to amplify the inflammatory response [12,
13]. To our knowledge, there is no evidence of a directAs reported by others, the 5/6Nx group presents a pro-
gressive rise in serum creatinine, whereas in contrast, suppressive effect of MMF on cytokine production by
intrinsic renal cells. However, this drug reduces cell ad-the rats with 5/6 reduction in renal mass treated with
MMF showed only a modest increment in serum creati- hesion molecules in endothelial cells [16], and there is a
well-defined inhibition of the production of all lympho-nine that remained at steady levels from the fourth to
the eighth week (Fig. 1). cyte and macrophage-derived cytokines and growth fac-
tors. Specifically, platelet-derived growth factor, inter-The histologic findings are in accordance with the renal
function data. The number of glomeruli with segmental leukin 2, tumor necrosis factor a, and transforming
growth factor-b are profoundly reduced [33]. Suppres-and global sclerosis is substantially reduced with MMF
treatment. Moreover, the percentage of glomeruli with sion of macrophage-derived platelet-derived growth fac-
tor should prevent further activation of the mesangialthese changes (Fig. 5 A, B) remains essentially unchanged
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Fig. 5. Intercellular adhesion molecules in remnant kidneys four weeks after 5/6Nx. Intense interstitial infiltration of cells expressing CD18 in
kidney from untreated rat (A) is contrasted with the negative appearance of the kidney from a rat treated with MMF (B). Intense glomerular
expression of CD54 in untreated 5/6Nx rat (C) contrasts with moderate expression of CD54 in 5/6Nx rats treated with MMF (D).
cells, in addition to limiting amplification of the prolifera- It is interesting that a similar increment in glomerular
volume was found in the 5/6Nx and the 5/6NxMMFtive reaction of infiltrating cells. Suppression of macro-
phage-derived transforming growth factor-b should have groups. This finding firstly suggests that the hemody-
namic disturbances that trigger glomerular hypertrophya beneficial effect on glomerulosclerosis by limiting the
synthesis and favoring the degradation of extracellular are similar in both groups of rats with renal ablation, and
secondly suggests that renal hypertrophy is unaffected bymatrix by renal metalloproteinases [36, 37].
An additional influence that may induce synthesis of MMF treatment. This is in contrast with the reduction
in the renal hypertrophy and hyperplasia associatedchemokynes is the generation of reactive oxygen species.
Nath, Croatt and Hostetter have shown that oxidant with other immunosuppressive drugs such as cyclospor-
ine A [39].stress is increased in the 5/6Nx model [4], and our studies,
in addition to confirming their findings, have shown that Lymphocyte (CD43-positive cells) and macrophage
(ED1-positive cells) infiltration is comparable in theurinary MDA is significantly reduced by MMF treatment
from the first to the sixth week after nephrectomy (Fig. MMF-treated group and the sham-operated group at
four weeks after surgery. In contrast, the 5/6Nx group3). This effect of MMF is likely the result of suppression
of the inflammatory infiltrate, but by itself, a reduction shows the cellular infiltration of the remnant kidney re-
ported previously by others [10–13, 28]. These findingsin reactive oxygen species would reduce the expression
of MCP-1, RANTES, and ICAM-1 in the mesangial cells indicate that MMF administration was capable of effec-
tively counteracting the infiltration and proliferative[reviewed in 34]. In addition, a decrease in oxidative
stress would eliminate a stimulus for apoptosis, which is stimuli triggered by the glomerular hypertension.
Expression of adhesion molecules has not been stud-an early event in the remnant kidney model [38].
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